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Recently, gene therapy with rhTrim5α, an innate restriction factor which blocks HIV-1 at a post entry
step, have been shown to be applicable as treatment in vitro. However, HIV-1 might adapt to replicate in
the presence of rhTrim5α due to its high mutation rate. Here we observed that two different HIV-1
isolates were able to replicate in cells expressing high levels of rhTrim5α. Escape mutations were found
in the conserved regions of the viral genome, Gag and p51 RT subunit. Furthermore, the escape muta-
tions, predominantly in the capsid and p51 RT, altered viral sensitivity to modiﬁed huTrim5α R332P and
R335G variants, with only a minor effect on the replication capacity in primary PBMCs. Therefore, gene
therapy with rhTrim5α might be suitable for HIV-1 treatment, however the virus will eventually escape
the pressure by gaining mutations in the conserved regions of the viral genome without any severe
ﬁtness cost.
& 2015 Elsevier Inc. All rights reserved.Introduction
Worldwide, 35 million people are living with HIV-1, and yet
only 20% have access to combination anti-retroviral therapy
(cART). The use of cART upon daily intake successfully suppresses
viral replication, reduces transmission rates of the virus and pro-
longs life expectancy of infected patients. However, prolonged use
of this therapy leads to drug toxicity and viral resistance (Palella et
al., 1998). Furthermore, HIV-1 replication reoccurs upon cART
discontinuation even after long term viral suppression, indicating
that patient is not cured and that the virus persists in latent viral
reservoirs (Wong et al., 1997; Finzi et al., 1999). Clearly new
therapies need to be developed to treat and possibly cure HIV-1
infection (Cohen, 2011).
Currently, a functional cure from HIV-1 has been achieved in
only one patient, after two allogeneic stem-cell transplantations
with CD34þ peripheral blood stem cells (Hematopoietic Stem
Cells (HSC)) from a donor who lacks expression of HIV-1 co-
receptor CCR5, which provided the patient with a new immune
system resistant to HIV-1 infection (Hutter et al., 2009; Allers et
al., 2011). Since only o1% of the Caucasians and almost none of
the African population are homozygous for the deletion in the
CCR5 genome (Dean et al., 1996; Samson et al., 1996; Liu et al.,
1996), an HLA-matched donor lacking a functional CCR5 gene
would be difﬁcult to ﬁnd. However, host cell deprivation ofþ31 20 5669756.
otstra).essential HIV-1 co-factors by means of gene therapy might be a
promising new treatment option. Numerous RNA and protein-
based gene therapy strategies have been explored to target the
host protein CCR5 to block HIV-1 infection (2010;Anderson and
Akkina, 2007, 2008). Yet, those CCR5-targeting therapies are not
applicable for circumventing infection with CXCR4-using HIV-1
variant (Oberlin et al., 1996). Furthermore, gene therapy using
shRNAs that target highly conserved HIV-1 sequences have been
explored (Berkhout, 2009; DiGiusto et al., 2010). However, tar-
geting HIV directly have been proven ineffective due to rapid
turnover and error-prone nature of the virus, the virus could
escape by single point mutation in the targeted conserved region
(Senserrich et al., 2008).
The naturally occurring restriction factor, Trim5α (Tripartite
interaction motif 5α) has been explored in gene therapy applica-
tions against HIV-1 (Anderson and Akkina, 2005, 2008). Trim5α
targets the incoming viral capsid to be degraded by a proteasome-
dependent mechanism, thereby disrupting reverse transcription
and blocking infection (Rold and Aiken, 2008; Stremlau et al.,
2004). The antiviral activity of Trim5α protein is species speciﬁc.
HIV-1 replication is completely blocked by Trim5α protein from
rhesus macaque (rhTrim5α) whereas human Trim5α (huTrim5α)
only minimally interferes with HIV-1 replication (Stremlau et al.,
2004; Sakuma et al., 2007; Kootstra et al., 2003; Rits et al., 2007).
However, amino acid changes in the SPRY (B30.2) domain of the
huTrim5α gene can increase the antiviral activity of the protein
(Li et al., 2006; Yap et al., 2005; Pham et al., 2010). The efﬁcacy of
rhTrim5α to inhibit HIV-1 in gene therapy setting has been shown
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Akkina, 2005, 2008; Walker et al., 2012).
Although rhTrim5α seemed to be a good candidate for HIV-1
treatment in a gene therapy setting, the virus might be able to
adapt to rhTrim5α due to its high mutation rate as result of lack of
proof reading by the reverse transcriptase enzyme. In this study,
we have successfully adapted two HIV-1 isolates to replicate in
presence of rhTrim5α in in vitro cultures. Escape mutations
responsible for escape from rhTrim5α were seen in Gag and pol-
p51 subunit. We have characterized the impact of the escape
mutations on the sensitivity of the virus to Trim5α and replication
capacity in primary cells.Results
HIV-1 escaped Trim5α-mediated pressure in vitro
To determine whether HIV-1 can escape from rhTrim5α
mediated inhibition, longterm cultures of HIV-1 were performed
in cells expressing high levels of rhTrim5α. Two different HIV-1Fig. 1. Replication kinetics of NL4-3 Bal containing wild type (A) and CypA-BR mutant (B
of U87.CD4.CCR5 cells expressing rhTrim5α. Virus replication is measure by p24 productio
CD4.CCR5 cells containing the indicated percentage of U87.CD4.CCR5 cells expressing rhvariants were used: NL4-3 Ba-L (WT) and NL4-3 Ba-L containing
four mutations in the capsid protein (L215V, H219Q, A220P, and
I223V) (CypA-BR) that have previously been associated with lower
sensitivity to human and rhesus Trim5α (Kootstra et al., 2003,
2007). Four parallel cultures of U87 expressing CD4 and CCR5
(U87.CD4.CCR5) were inoculated with WT or CypA-BR mutant
viruses and the culture supernatants were serially passaged onto
mixed cultured of U87.CD4.CCR5 cells highly expressing rhTrim5α
(U87.CD4.CCR5 rhTrim5α) and overtime decreasing percentages of
U87.CD4.CCR5 cells (Fig. 1). In cultures inoculated with WT variant,
viral replication as reﬂected by p24 production, strongly decreased
when the proportion of U87.CD4.CCR5 rhTrim5α cells was
increased to 95–99% (Fig. 1a). Virus replication remained detect-
able at lower levels until day 98 after the culture. In culture WT-1,
WT-2 and WT-4, low viral replication was observed between day
105 till 133 and a rebound in viral replication was evident at day
147. Interestingly, virus replication in culture WT-3 remained
detectable throughout the whole culture period with viral repli-
cation peaks at day 112–119 and 147–154.
In the cultures inoculated with CypA-BR mutant variant, a
similar decrease in viral replication was observed when the) capsid during in vitro culturing in U87.CD4.CCR5 cells with increasing percentages
n in the culture supernatant. Black arrows specify the p24 value obtained from U87.
Trim5α.
Table 1
Sequence analysis of gag and pol of in vitro evolved rhTrim5α escape viruses.
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99% (Fig. 1b). In culture CBR-1 and CBR-2, a transient increase in
viral replication was observed at day 77–84 (CBR-1) or day 98–105
(CBR-2), which was followed by a second increase in viral repli-
cation at day 133 that continued throughout the remainder of the
culture period. Viral replication in CBR-3 became detectable at day
133 after the onset of the culture, but remained at low levels until
day 154 when a clear rebound of viral replication was detected. In
viral culture CBR-4, a transient peak in viral replication was
observed at day 77–84 and 119, whereas a more continuous
replication was observed from day 161 onwards (Fig. 1b). These
data showed that HIV-1 evolved to escape from rhTrim5α-medi-
ated restriction in vitro.
Mutations in gag and pol are associated with escape of HIV-1 from
rhTrim5α
Since the Trim5α protein interacts with the incoming viral
capsid in the cytoplasm (Rold and Aiken, 2008; Stremlau et al.,
2004), we performed sequence analysis of the gag region of the
in vitro evolved rhTrim5α escape variants. RNA was isolated from
virus containing supernatant of the in vitro evolved cultures at the
end of culturing period. From the in vitro evolved rhTrim5α escape
wild type viruses, we observed sequence variations in the matrix
(MA) and capsid (CA) domains of the gag region in 3 out of
4 viruses (WT-1, WT-3, and WT-4) (Table 1). In in vitro evolved
rhTrim5α escape virus WT-1, we observed 10 mutations in gag, ofwhich 1 amino acid was located in the MA domain and 9 in the CA
region (Table 1). Three of the observed CA mutations (L215M,
V218M and H219Q) were located in the CypA-binding region of
the viral capsid (Table 1). In the WT-3 and WT-4 variants, amino
acid changes were only observed in MA domain of the gag region
(Table 1). WT-3 virus harbored the D14N mutation, which neu-
tralized the negative charge of aspartic acid, and E52K resulted in a
charge change at that position from negative to positive. Further-
more, the WT-4 virus harbored the E to K mutation at two posi-
tions, 12 and 52, in MA which resulted charge change from
negative to positive. Additionally, WT-4 contained the V46I and
D102N mutation, which neutralized the negative charge at
position 102.
From the in vitro evolved CypA-BR mutant viruses, the parental
215V, 219Q, 220P, and 223V mutations in the CypA binding region
remained present in all obtained variants. Interestingly, the in vitro
evolved viruses had additionally gained only 1 escape mutation
each in the CA region, P225S in CBR-1, I261V in CBR-3, and R214K
in CBR-4 variant.
It has been demonstrated that mutations in the RT gene inﬂu-
ence the viral sensitivity to rhTrim5α (Yang et al., 2013). Indeed we
observed mutations in the pol-p51 subunit in ﬁve of the in vitro
evolved rhTrim5α escape variants. Although most amino acid
changes were unique for a single in vitro evolved variant, sub-
stitutions I244M, and N255D (which resulted in change of amino
acid charge) were observed in WT-1 and WT-4 variants. Gain of
positively charged amino acid was observed in in vitro evolved
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respectively). In the in vitro evolved variants progeny of CypA-BR
parental virus, we observed 2 mutations in the pol-p51 subunit of
CBR-1, whereas 6 mutations in this region were observed in CBR-3.
Interestingly, amino acid substitutions Q102K, and K122E in CBR-3
resulted in changes in amino acid charge. Our data showed that
HIV-1 escape from rhTrim5α-mediated inhibition resulted in
substitutions in gag and pol region of the virus.Escape variants from rhTrim5α in vitro have altered sensitivity to
different huTrim5α variants
To determine whether mutations in gag and pol gained in the
in vitro evolved rhTrim5α escape variants affect viral sensitivity to
different huTrim5α variants, we infected U87.CD4.CCR5 cell lines
stably expressing rhTrim5α, huTrim5α or modiﬁed huTrim5α
(carrying the R332P or R335G amino acid change) with increased
antiviral activity (Li et al., 2006; Yap et al., 2005; Pham et al., 2010)
with 100TCID50 of the different viruses. Replication of the parental
viruses WT and CypA-BR was inhibited in cells expressing Trim5α
proteins when compared to the non-transduced cells (supple-
mentary Table 1). All in vitro evolved rhTrim5α escape variantsFig. 2. Virus production of in vitro evolved rhTrim5α escape and derivative variants in cel
mutations in the indicated viral genes. Normalized p24 values (relative to infection in pre
Student's T test. Whiskers represent the standard deviation.
Table 2
Replication of in vitro evolved rhTrim5α escape viruses in U87 cells expressing
different Trim5α variants.were able to infect huTrim5α expressing cells more efﬁciently
when compared to non-transduced cells (Supplementary Table 1).
The parental WT virus could efﬁciently be inhibited by the
rhTrimα, huTrimα R332P and huTrimα R335G proteins (Table 2),
with virus production levels o30% in comparison to virus repli-
cation in presence of huTrim5α. Furthermore, all 4 in vitro evolved
WT viruses could still be inhibited by rhTrim5α (Table 2). The
in vitro evolved variants lost sensitivity to huTrim5α R332P and
R335G mediated inhibition (Table 2).
The parental CypA-BR virus was inhibited by rhTrim5α,
huTrim5α R332P and huTrim5α R335G proteins and showed
o45% of virus production in presence of these Trim5α variants in
comparison to huTrim5α (Table 2). The four in vitro evolved
Trim5α escape variants obtained from CypA-BR virus could still be
inhibited by rhTrim5α (Table 2). However, these viruses lost sen-
sitivity to the antiviral activity of modiﬁed huTrim5α variants
(R332P and R335G) when compared to the parental CypA-BR virus
(Table 2).
Next, we analyzed whether localization of mutations in differ-
ent regions of the viral genome gained during escape from
rhTrim5α pressure affect virus sensitivity to rhTrim5α and mod-
iﬁed huTrim5α proteins. We divided the viruses into three groups,
with mutations only observed in gag region (including the CBR-
parental virus with 4 mutations in gag), pol-p51 region or both in
gag-pol-p51 regions. The WT virus was used as a reference virus
(no mutation). The relative (to huTrim5α) infectivity of the viruses
in the presence of rhTrim5α and modiﬁed huTrim5α were com-
pared. Increased virus replication was observed in the presence of
modiﬁed huTrim5α proteins irrespective of the location of the
mutations (Fig. 2).
Trim5α sensitivity of viruses with escape mutations in CA
Our data suggest that mutations in the different viral proteins
(Gag and Pol-p51) affect viral sensitivity to rhTrim5α and modiﬁed
huTrim5α proteins. Since Trim5α is known to interact with the
viral capsid, we assessed the role of the observed mutations in CA
in the in vitro evolved rhTrim5α variants in altering virus sensi-
tivity to Trim5α. We introduced different combinations of the
observed of escape mutations in CA into the backbone of full
length replicating NL4-3 BAL (WT and CypA-BR) viruses (Table 3)
and analyzed the effect these mutations on Trim5α mediated
inhibition.
In contrast to the parental viruses, all derivative rhTrim5α
escape variants were able to infect huTrim5α expressing cells
more efﬁciently than the non-transduced cells (supplementary
Table 1). The rhTrim5α protein was able to inhibit all derivative
variants from the parental WT virus (Table 4). Additionally, all the
WT derivative viruses became insensitive to both modiﬁed
huTrim5α variants (R332P and R335G) mediated inhibition
(Table 4). The huTrim5α R332P variant was unable to blockls expressing Trim5α variants. Viruses were grouped based on the number of escape
sence of huTrim5α) at day 3 are represented and were compared using the unpaired
Table 4
Replication of derivative WT and mutant viruses in U87 cells expressing different
Trim5α variants.
Table 3
Sequence of artiﬁcial rhTrim5α escape mutants in Gag.
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could still be partial inhibited by this protein. Furthermore, WT-D
and WT-E almost completely lost sensitivity for huTrim5α R335G
mediated inhibition, while the other WT derivative viruses were
partially inhibited by this protein.
Of the viral variants derived from the parental CypA-BR mutant
virus, CBR-C became relative insensitive to rhTrim5α and com-
pletely lost sensitivity to modiﬁed huTrim5α proteins, while
replication of CBR-A and CBR-B was partially inhibited by both
modiﬁed huTrim5α proteins (Table 4).
Replication capacity of rhTrim5α escape variants in primary PBMC
Next, we investigated whether escape from rhTrim5α-
mediated restriction affects viral replication capacity in primary
cells. PHA-stimulated PBMCs were inoculated with (100TCID50)
in vitro evolved rhTrim5α escape variants and derivative mutant
viruses and virus production was analyzed with p24 ELISA everyday for a period of 18 days. Virus production at day 11 was com-
pared to that of the parental viruses (WT and CypA-BR). Our data
showed that one out of 4 in vitro evolved rhTrim5α escape derived
from WT virus (WT-1), which harbored 9 and 4 amino acid
mutations in Gag and p51 RT subunit respectively, showed an
increased viral replication capacity as compared to the WT par-
ental virus (Fig. 3a). The derivative mutant variants WT-A, WT-D
and WT-E showed signiﬁcantly lower virus replication capacity
when compared to the WT parental virus (Fig. 3a).
Two out of 4 of the in vitro evolved rhTrim5α escape variants
derived from the CypA-BR mutant virus (CBR-1 and CBR-2)
showed an increased viral replication capacity in PBMC whereas
1 out of 4 in vitro evolved viruses (CBR-3, with 6 mutations in p51
RT domain) showed a decreased viral replication capacity at day
14 in comparison to the parental CypA-BR virus (Fig. 3b). Inter-
estingly, derivative mutant variants derived from the CypA-BR
mutant virus (CBR-A, CBR-B, and CBR-C) carrying only the R214K,
P225S or I261V mutations in Gag did not alter virus replication in
primary PBMCs. These data suggest that mutations in gag and pol-
p51 gained during escape from rhTrim5α-pressure may alter viral
replication capacity in primary PBMCs.Discussion
Although gene therapy approaches using the antiviral Trim5α
protein are very promising for HIV-1 gene therapy (Anderson and
Akkina, 2005, 2008; Walker et al., 2012), it is also very likely that
this approach might eventually be hampered by the development
of viral escape mutations. Indeed, we and others have already
demonstrated that mutations in the viral determinant involved in
Trim5α restriction, which is located in the CypA binding region of
the HIV-1 capsid, can develop during natural HIV-1 infection and
interfere with the sensitivity of the virus to Trim5α (Kootstra et al.,
2003; Chatterji et al., 2005; Ikeda et al., 2004; Kootstra et al.,
2007).
Here, we showed that HIV-1 was able to escape from
rhTrim5α-mediated inhibition in vitro which is in agreement with
previous ﬁndings (Pacheco et al., 2010; Sollet al., 2013; Chatterji
et al., 2005). We have identiﬁed 12 mutations in capsid that were
associated to escape of the NL-4-3 Ba-L virus from rhTrim5α-
mediated inhibition. Four out of 9 mutations were located in the
CypA-binding region of the viral capsid (L215M, V218M, H219Q
and P225S). Three mutations (V218M, H219Q, M228I) were found
in vivo in previous reports (Chatterji et al., 2005; Kootstra et al.,
2007). Additionally, mutations T242N and G248A found in one of
Fig. 3. Replication kinetics of in vitro evolved rhTrim5α escape and derivative variants in primary PBMCs. Normalised mean p24 levels on day 14 are represented and were
compared using the unpaired Student's T test. Whiskers represent the standard deviation. Statistical signiﬁcance is indicated as follows: *po0.05, **po0.01.
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HLA-B57 restricted CTL pressure, viruses harboring these muta-
tions have reduced viral ﬁtness and increased sensitivity for
huTrim5α (Granier et al., 2013; Gijsbers et al., 2013). Our data
showed that derivative virus carrying only T242N and G248A
escape mutations were still sensitive to rhTrim5α to same level of
the WT-parental virus, but almost completely abolished restriction
from modiﬁed huTrim5α proteins, with cost of viral ﬁtness in
primary PBMCs. Furthermore, when other escape mutations were
added into the combination, particularly in the CypA-binding
region of the viral capsid, sensitivity to modiﬁed huTrim5α pro-
teins were decreased but not to the level of sensitivity in virus
carrying only the T242N and G248A mutations. Our data is in
agreement with previous ﬁndings that the presence of these
escape mutations in the capsid region have reduced viral sensi-
tivity to Trim5α variants and altered viral ﬁtness in primary PBMCs
(Granier et al., 2013). Interestingly, the mutations described here
might also be beneﬁcial for the development of lentiviral vectors
for gene therapy and these mutations might be able to enhance
transduction efﬁciency of the lentiviral vector in certain cell types.
Although escape mutations from rhTrim5α were mostly
reported to occur in the viral capsid (Kootstra et al., 2003; Chatterji
et al., 2005; Ikeda et al., 2004; Kootstra et al., 2007), we observed
6 amino acid changes (E12K, D14N, V46I, E52K, D102N, and
S126N) in the matrix domain of Gag. Our ﬁndings added to a
previous study that described R20W and S126R mutations in MA
as escapes from rhTrim5α in vitro (Pacheco et al., 2010), however
these mutations were not observed in our study. The only in vitro
evolved rhTrim5α-escape variant (WT-3) with mutations strictly
in MA region (D14N and E52K) was still sensitive to rhTrim5α,
whereas sensitivity to inhibition by the modiﬁed huTrim5α var-
iants was completely abolished (R332P) or strongly decreased
(R335G). The WT-4 variant containing MA mutations as well as
mutations in the pol-p51 regions, showed a similar Trim5α sen-
sitivity pattern as WT-3, suggesting that mutations in MA alone or
in combination with pol-p51 contribute to escape from Trim5α-
mediated inhibition.
Previously, we demonstrated that mutations in the HIV-1
capsid (L215V, H219Q, A220P, and I223V) were able to abrogatepost-entry block in simian cells (Kootstra et al., 2003), allowing
efﬁcient lentiviral transduction in those cells (Rits et al., 2007). Our
data showed that HIV-1 variant carrying the four mutations
(CypA-BR) remained sensitive to rhTrim5α when the protein was
overexpressed in U87.CD4.CCR5 cells. Moreover, adaptation of the
CypA-BR mutant virus from the overexpressed rhTrim5α protein
was achieved after 120 days of culture and only resulted in
1 additional mutation in viral capsid per escape variant (R214K,
P225S, or I261V) in three out of four cultures. Interestingly, our
derivative mutants data showed that presence of the additional
single escape mutation in Gag indeed reduced viral sensitivity to
Trim5α variants but did not cause any changes in viral ﬁtness. In
the in vitro evolved CBR-2 variant, no escape mutations in gag nor
pol-p51 genes was observed, however the virus had clearly adap-
ted to the presence of the different Trim5α proteins as compared
to the parental virus was observed. This suggests that viral adap-
tation might also occur in other regions of the virus that have not
yet been associated with Trim5α resistance.
Recently it has been demonstrated that inhibition of reverse
transcription resulted in an increase of viral core stability (Yang
et al., 2013) and this might also affect sensitivity of the virus to
Trim5αmediated inhibition. In our study, we observed amino acid
changes in the p51 RT subunit region in the Pol protein in 5 out of
8 in vitro evolved rhTrim5α escape variants. Indeed, mutations in
pol-p51 (A26T, G196R, R206G, and E296K) have previously been
associated to escape from rhTrim5α, in which 3 out of 4 resulted in
change of amino acid charge (Pacheco et al., 2010). Here, we
observed that an in vitro evolved rhTrim5α escape variant derived
from WT virus (WT-2) with only a Q102K mutation in the pol-p51
subunit also has reduced viral sensitivity to Trim5α-mediated
inhibition and maintained viral ﬁtness. In the in vitro evolved
rhTrim5α escape variant derived from the CypA-BR mutant virus
(CBR-1), the V21I and T200A mutations in pol-p51 subunit ren-
dered the virus less sensitive to huTrim5α R332P in comparison to
virus with only P225S CA mutation (CBR-A). Collectively, our
ﬁndings conﬁrm that changes in RT contribute to viral sensitivity
to rhTrim5α.
We did not observe complete abolishment of rhTrim5α
restriction of the in vitro rhTrim5α escape variants, conﬁrming
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observed that the region of the viral genome in which the escape
mutations were located, did not necessarily dictate viral sensitivity
to rhTrim5α. Indeed, we were able to gain an escape variant from
rhTrim5α only after at least 119 days of culture in cells expressing
high levels of rhTrim5α protein, which was more than double the
time needed for a CCR5 tropic HIV-1 to evolve into a CXCR4-using
variant in vitro (Edo-Matas et al., 2011). Plausibly, a synergy of
several mutations in both gag and pol regions of the virus is
essential to provide an optimal viral capsid stability and rate of
reverse transcription for efﬁcient abolishment of rhTrim5α-
mediated restriction. Our data contributes to the theory that
complete escape from rhTrim5α is difﬁcult to achieve, since the
changes in virus are observed in gag and reverse transcriptase,
which are very conserved regions. The introduction of just a single
mutation that allows viral escape may have severe consequences
for viral ﬁtness and require compensatory mutations for optimal
viral replication in the presence of the restriction factor (Pacheco
et al., 2010).
Additionally, we have demonstrated that viruses with escape
mutations from rhTrim5α have become less sensitive to or com-
pletely abolished restriction by modiﬁed huTrim5α R332P and
R335G proteins, in agreement with ﬁndings by others (Maillard et
al., 2011; Veillette et al., 2013; Soll et al., 2013). Overall, HIV-1
variants studied here seemed to be more sensitive to the antiviral
activity of the modiﬁed huTrim5α R335G variant in comparison to
the R332P variant.
Moreover, 8 out of the 9 rhTrim5α escape mutations in Gag
(I147V, V159I, L215M, V218M, H219Q, M228I, T242N and G248A)
were previously associated with escape from HLA-B57 restricted
CTL pressure (Gijsbers et al., 2013; Bailey et al., 2008; Navis et al.,
2007; Jansen et al., 2005). This ﬁnding supports previous obser-
vations that Trim5α links innate and adaptive immunity, and that
viral sensitivity to Trim5α determines susceptibility to HLA-B57
CTL pressure (Battivelli et al., 2011; Granier et al., 2013).Conclusions
Our ﬁndings showed that HIV-1 can escape from rhTrim5α-
mediated inhibition by gaining escape mutations in viral capsid,
matrix and reverse transcriptase genes. The in vitro development of
these different combinations of mutations took more than 119
days, suggesting that mutations supporting viral escape from
rhTrim5α, in these conserved regions require compensatory
mutations to maintain viral ﬁtness.Materials and method
Cell isolation and cultures
PBMC's were isolated from buffy coats of healthy blood donors.
Written informed consents were obtained from all donors in
accordance with the ethical principles set out in the declaration of
Helsinki. This study was approved by the Medical Ethics Com-
mittee of the Academic Medical Center and the Ethics Advisory
Body of the Sanquin Blood Supply Foundation in Amsterdam, The
Netherlands. Peripheral blood mononuclear cells (PBMCs) were
isolated from buffy coats using Lymphoprep (Axis-Shield, Olso,
Norway) density gradient centrifugation, pooled and cryopre-
served. After thawing, the PBMC pool was stimulated for three
days in Iscoves' Modiﬁed Dulbecco's Medium (IMDM) supple-
mented with 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin,
5 mg/ml ciproxin (Bayer, Mijdrecht, The Netherlands) and 1 mg/ml
phytohaemagglutinin (PHA; Remel Europe, Dartford, England, UK)at a cell density of 5106 cells/ml in a humidiﬁed 10% CO2 incu-
bator at 37 °C. PBMC cultures were continued in IMDM supple-
mented with 10% FCS, 20 U/ml recombinant interleukin 2 (rIL2;
Chiron Benelux, Amsterdam, The Netherlands, 5 mg/ml polybrene
(Sigma, Zwijndrecht, The Netherlands), 100 U/ml penicillin and
100 mg/ml streptomycin at a cell density of 1106/ml in a humi-
diﬁed 10% CO2 incubator at 37 °C. HEK-293 T cells (ATCC) were
cultured in Dulbecco Modiﬁed Eagle's Medium (DMEM) supple-
mented with 10% heat inactivated fetal calf serum (FCS) and
penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37 °C
humidiﬁed atmosphere supplemented with 10% CO2. U87 cell lines
stably expressing CD4 and wild-type CCR5 co-receptor (a gift from
Liselotte Antonsson, Lund University) and TZMbl cells (a gift from
DC Monteﬁore, Duke University Medical Centre) were cultured in
IMDM supplemented with 10% fetal calf serum (FCS) and penicillin
(100 U/ml) and streptomycin (100 μg/ml) at 37 °C humidiﬁed
atmosphere supplemented with 10% CO2.
Generation of cells stably expressing Trim5α variants
Trim5α variants (human, rhesus, human R332P and human
R335G) were cloned into a lentiviral vector (LV) construct carrying
CAG promoter and GFP (Kootstra et al., 2003). HIV-1 based lenti-
viruses expressing the Trim5α variants were produced by calcium
phosphate transfection of 293 T cells with the lentiviral vector (LV)
construct, the packaging construct for gag/pol, vesicular stomatitis
virus glycoprotein envelope (pCMV-VSV-G) and rev (pRSV-rev) as
described previously (Dull et al., 1998). Infectious LVs were har-
vested at 48 and 72 h after transfection and ﬁltered through a
0.22 μm ﬁlter. The LVs were concentrated by ultracentrifugation
(2 h at 50,000 g). Virus titers were quantiﬁed by determination of
the 50% tissue culture infectious dose (TCID50) on 293 T cells. After
24 h, the infected cells were analyzed by FACS. Next, the produced
lentiviruses were used to transduce U87.CD4.CCR5 cells
(MOI¼20). Transduction efﬁciency were analyzed by FACS and
western blot.
Virus productions
For the production of replicating NL4-3 Bal clones, the full
length HIV-1 constructs (containing wild type and CypA-BR cap-
sids) were transfected into 293 T cells using the calcium phosphate
method. Viruses were harvested at 48 and 72 h after transfection
and ﬁltered through a 0.22 μm ﬁter. Virus titers were quantiﬁed by
determination of the TCID50 on luciferase reporter TZMbl cells.
After 48 h, luciferase substrate (0.83 mM ATP, 0.83 mM D-luciferin
(Duchefa Biochemi BV), 18.7 mM MgCl2, 0.78 μM Na2H2P2O7,
38.9 mM Tris–HCl pH 7.8, 0.39% glycerol, 0.03% Triton X-100, and
2.6 μM dithiothreitol) was added and luminescence was measured
for 1 second per well using the Centro LB 960 (Berthold
technologies).
VSV-G pseudotyped single round luciferase viruses were pro-
duced by cotransfection of pNL4-3.Luc.R-E- constructs containing
wild type or the CypA-BR mutant capsids (which were placed in
the pNL4-3.Luc.R-E- construct by site directed mutagenesis) and
the pCMV-VSV-G in 293 T cells using the calcium phosphate
method. Infectious viruses were harvested at 48 and 72 h after
transfection and ﬁltered through a 0.22 μm ﬁlter. Virus titers were
quantiﬁed by determination of the TCID50 on 293 T cells. After
48 h, infected cells were washed with PBS and luciferase substrate
was added and luminescence was measured.
HIV-1 variants containing mutations in the capsid protein was
constructed as previously described (Gijsbers et al., 2013). For the
production of replicating NL4-3 Bal clones containing the desired
mutations, the mutated gag insert was ligated into the full length
molecular NL4-3 Bal clone using In-Fusions HD Cloning kit as
L.C. Setiawan, N.A. Kootstra / Virology 486 (2015) 239–247246described by the manufacturer (Clontech
s
Laboratories, Inc.). The
full length NL4-3 Bal molecular clones were then transfected into
293 T using the calcium phosphate method. Virus production from
the 293 T cells was analyzed at day 3 and 7 after transfection using
an in house p24 ELISA (Tersmette et al., 1989). Virus stocks were
grown on PHA-stimulated PBMC and virus titers were quantiﬁed
by determination of the TCID50 on luciferase reporter TZMbl cells.
The gag regions of the obtained viruses were sequenced as pre-
viously described to conﬁrm the introduction of mutations (Gijs-
bers et al., 2013).
In vitro evolution of HIV-1 to abolish rhTrim5α-mediated pressure
To obtain HIV-1 variants which are resistant to rhTrim5α-
mediated pressure, we used an adjusted protocol which was
previously described (Edo-Matas et al., 2011). Six parallel cultures
of 4104 U87.CD4.CCR5 cells per well plated in a 24-well tissue
culture plate were inoculated with 1000TCID50 of NL4-3 Bal (car-
rying wild type or CypA-BR capsids). Every week, the viral
supernatant was transferred into fresh co-cultures of U87.CD4.
CCR5 cells and U87.CD4.CCR5 expressing rhTrim5α cells in which
percentages was increased over time (30%, 50%, 70%, 90%, 97% and
99% at weeks 1, 2, 3, 4, 5, and 6 respectively). Subsequently, virus
production was monitored weekly by an in house p24 ELISA
(Tersmette et al., 1989).
Infections
To test the antiviral activity of the different Trim5α variants,
U87.CD4.CCR5 cells lines stably expressing a Trim5α variant were
cultured in a 96-well white plates (Nunc, Langenselbold, Germany)
at a density of 8103 cells per well, and inoculated at day 1 with
50, 100 and 200 TCID50 of NL4-3 luciferase virus strain. After 48 h,
the infected cells were washed with PBS and luciferase substrate
was added and luminescence was measured.
For infection of replicating NL4-3 BAL viruses with mutations in
gag region, U87.CD4.CCR5 cell lines stably expressing a Trim5α
variant were cultured in a 96-well tissue culture plates (Nunc,
Langenselbold, Germany) at a density of 8103 cells per well, and
inoculated at day 1 with 200TCID50 of the virus. 24 h post inocu-
lation, unbound virus particles were washed with medium. At
3 and 7 days post inoculation, virus production was determined
using an in-house p24 ELISA. Statistical analysis were done using
GraphPad Prism version 5.01 for Windows.
To determine the viral replication rates of HIV-1 variants,
2106 PHA-stimulated pooled PBMC were inoculated with
100TCID50 per virus variant for 2 h at 37 °C in a shaking water
bath in a total volume of 1,5 ml. Subsequently, the inoculated
PBMC were washed with 5 ml of IMDM supplemented with 10%
FCS, and cultured in IMDM supplemented with 10% FCS, 20 U/ml
rIL2, 5 mg/ml polybrene, 100 U/ml penicillin and 100 mg/ml strep-
tomycin (PBL medium) at a cell density of 1106 per ml in a
humidiﬁed 10% CO2 incubator at 37 °C. On day 5,8,11 and 14 after
inoculation, 1106 fresh PHA-stimulated pooled PBMC in 1 ml of
PBL medium were added to the cultures. Samples for determina-
tion of p24 antigen production were harvested every day after
inoculation. All samples were tested for p24 antigen production
simultaneously at the end of the experiment using an in-house
p24 ELISA (Tersmette et al., 1989). Statistical analysis were done
using GraphPad Prism version 5.01 for Windows.
DNA isolation, PCR and sequencing
Total DNA was isolated from infected cells using a modiﬁcation of
the L6 isolation method (Kootstra and Schuitemaker, 1999). Gag PCR
ampliﬁcation was performed as previously described (Gijsbers et al.,2013; Navis et al., 2008). Pol PCR ampliﬁcation was performed with
PCR using primers Pol outer fw (50-GGAAGGACACCAAATGAAAG-30)
and Pol outer rv (50-CCTTAGCTTTCCTTG-30) and a nested PCR with
primers Pol start fw (50-GTACTGAGAGACAGGCTAAT-30) and Pol end rv
(50-GGTGTTTTACTAATCTTTTCCATGTG-30) using the GoTaq polymerase
kit (Promega) and the following ampliﬁcation cycles: 5 min 30 s 94 °C,
30 cycles of 45 s 94 °C, 30 s 50 °C, 3 min 72 °C, followed by a 10min
extension at 72 °C and subsequent cooling at 4 °C. PCR products were
puriﬁed using ExoSAP-IT (USB) according to the manufacturer's pro-
tocol. Sequencing of pol-p51 subunit was performed using BigDye
Terminator v1.1 Cycle Sequencing kit (ABI Prism, Applied Biosystems)
as previously described (Gijsbers et al., 2013) with primers: Rnase w
(50-TGGTACCAGTTAGAGAAAGA-30), Rnase rv (50-CTTGTTCATTTCCTC-
CAATT-30), RT fw (50-TGTACAGAAATGGAAAAGGAAGGAA-30), and RT rv
(50-TGTCCTTTTCTGGCAGCACTAT-30)Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2015.09.017.Acknowledgments
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